Progress in Diagnosis and Treatment of Stroke Related with Patent Foramen Ovale

doi:10.3969/j.issn.1673-5765.2021.09.014

Abstract

Abstract: Patent foramen ovale (PFO) is strongly associated with cryptogenic stroke. For the patients with high-risk PFO, the appropriate treatment is decided by comprehensive evaluation including the high-risk PFO anatomical features, stroke imaging features and risk of paradoxical embolism (RoPE) scale, etc. Most of the existing research and guidelines support that PFO closer plus long-term antiplatelet therapy should be preferred for the patients with high-risk PFO, but the postoperative complications such as atrial fibrillation and occluder-related thrombosis may occur. Anticoagulation therapy and antiplatelet therapy are equally effective in preventing recurrent stroke.

Key words: Patent foramen ovale; Cryptogenic stroke; Cardiogenic stroke; Closure

摘要： 卵圆孔未闭（patent f oramen o vale，PFO）与卒中发病有明显的关联。应利用卒中高风险 PFO解剖学特征、卒中影像特征及反常栓塞风险量表等，经多科综合评估，选择患者最适合的治疗方案。多数现有研究及指南支持对于卒中高风险PFO患者，首选PFO封堵术加术后长期抗血小板治疗；单独抗凝治疗与单独抗血小板治疗在预防卒中复发上同效。

关键词: 卵圆孔未闭; 隐源性卒中; 心源性卒中; 封堵术

WANG Ze-Yi, YANG Ting-Ting, LIU Guang-Zhi. Progress in Diagnosis and Treatment of Stroke Related with Patent Foramen Ovale[J]. Chinese Journal of Stroke, 2021, 16(09): 960-966.

王泽祎, 杨亭亭, 刘广志. 卵圆孔未闭相关性卒中的诊治研究进展[J]. 中国卒中杂志, 2021, 16(09): 960-966.

References

[1] 国家卫生健康委员会脑卒中防治专家委员会房颤卒
中防治专业委员会，中华医学会心电生理和起搏分会，
中国医师协会心律学专业委员会. 中国心源性卒中
防治指南（2019）[J]. 中华心律失常学杂志，2019，23
（6）：463-484.
[2] ABDELGHANI M，EL-SHEDOUDY S A O，
NASSIF M，et al. Management of patients with
patent foramen ovale and cryptogenic stroke：an
update[J]. Cardiology，2019，143（1）：62-72.
[3] HE D，SHI Q，XU G J，et al. Clinical and infarction
patterns of PFO-related cryptogenic strokes and a
prediction model[J]. Ann Clin Transl Neurol，2018，5
（11）：1323-1337.
[4] FURLAN A J，REISMAN M，MASSARO J，et al.
Closure or medical therapy for cryptogenic stroke
with patent foramen ovale[J]. N Engl J Med，2012，
366（11）：991-999.
[5] KENT D M，THALER D E. Is patent foramen
ovale a modifiable risk factor for stroke
recurrence?[J/OL]. Stroke，2010，41（10 Suppl
1）：S26-S30[2020-07-12]. https：//doi.org/10.1161/
STROKEAHA.110.595140.
[6] HOMMA S，MESSÉ S R，RUNDEK T，et al. Patent
foramen ovale[J/OL]. Nat Rev Dis Primers，2016，
2：15086[2020-07-12]. https：//doi.org/10.1038/
nrdp.2015.86.
[7] JAFFRE A，GUIDOLIN B，RUIDAVETS J B，et al.
Non-obstructive carotid atherosclerosis and patent
foramen ovale in young adults with cryptogenic
stroke[J]. Eur J Neurol，2017，24（5）：663-666.
[8] MIRANDA B，FONSECA A C，FERRO J M. Patent
foramen ovale and stroke[J]. J Neurol，2018，265（8）：
1943-1949.
[9] MAZZUCCO S，LI L X，BINNEY L，et al.
Prevalence of patent foramen ovale in cryptogenic
transient ischaemic attack and non-disabling stroke
at older ages：a population-based study，systematic
review，and meta-analysis[J]. Lancet Neurol，2018，
17（7）：609-617.
[10] JONES E F，CALAFIORE P，DONNAN G A，et
al. Evidence that patent foramen ovale is not a risk
factor for cerebral ischemia in the elderly[J]. Am J
Cardiol，1994，74（6）：596-599.
[11] SCACCIATELLA P，MEYNET I，PRESBITERO
P，et al. Recurrent cerebral ischemia after patent
foramen ovale percutaneous closure in older patients：
a two-center registry study[J]. Catheter Cardiovasc
Interv，2016，87（3）：508-514.
[12] NAM K W，GUK H S，KWON H M，et al.
Diffusion-weighted imaging patterns according
to the right-to-left shunt amount in cryptogenic
stroke[J]. Cerebrovasc Dis，2019，48（1/2）：45-52.
[13] TURC G，LEE J Y，BROCHET E，et al. Atrial
septal aneurysm，shunt size，and recurrent stroke
risk in patients with patent foramen ovale[J]. J Am
Coll Cardiol，2020，75（18）：2312-2320.
[14] NAKAYAMA R，TAKAYA Y，AKAGI T，et al.
Identification of high-risk patent foramen ovale
associated with cryptogenic stroke：development of

a scoring system[J]. J Am Soc Echocardiogr，2019，

32（7）：811-816.
[15] LEE P H，SONG J K，KIM J S，et al. Cryptogenic
stroke and high-risk patent foramen ovale：the
DEFENSE-PFO trial[J]. J Am Coll Cardiol，2018，71
（20）：2335-2342.
[16] RIGATELLI G，DELL'AVVOCATA F，CARDAIOLI
P，et al. Permanent right-to-left shunt is the key
factor in managing patent foramen ovale[J]. J Am
Coll Cardiol，2011，58（21）：2257-2261.
[17] KENT D M，RUTHAZER R，WEIMAR C，et al. An
index to identify stroke-related vs incidental patent
foramen ovale in cryptogenic stroke[J]. Neurology，
2013，81（7）：619-625.
[18] THALER D E，RUTHAZER R，WEIMAR C，et
al. Recurrent stroke predictors differ in medically
treated patients with pathogenic vs other PFOs[J].
Neurology，2014，83（3）：221-226.
[19] PREFASI D，MARTÍNEZ-SÁNCHEZ P，FUENTES
B，et al. The utility of the RoPE score in cryptogenic
stroke patients ≤50 years in predicting a strokerelated
patent foramen ovale[J/OL]. Int J Stroke，
2016，11（1）：NP7-NP8[2020-07-12]. https：//doi.
org/10.1177/1747493015607505.
[20] WESSLER B S，KENT D M，THALER D E，et
al. The RoPE score and right-to-left shunt severity
by transcranial doppler in the CODICIA study[J].
Cerebrovac Dis，2015，40（1/2）：52-58.
[21] HOMMA S，SACCO R L，DI TULLIO M R，et
al. Effect of medical treatment in stroke patients
with patent foramen ovale：patent foramen ovale in
cryptogenic stroke study[J]. Circulation，2002，105
（22）：2625-2631.
[22] MAS J L，DERUMEAUX G，GUILLON B，et al.
Patent foramen ovale closure or anticoagulation vs .
antiplatelets after stroke[J]. N Engl J Med，2017，377
（11）：1011-1021.
[23] KHEIRI B，SIMPSON T F，OSMAN M，et al. Metaanalysis
of secondary prevention of cryptogenic
stroke[J]. Cardiovasc Revasc Med，2020，21（10）：
1285-1290.
[24] DIENER H C，CHUTINET A，EASTON J D，et
al. Dabigatran or aspirin after embolic stroke of
undetermined source in patients with patent foramen
ovale：results from RE-SPECT ESUS[J]. Stroke，
2021，52（3）：1065-1068.
[25] MEIER B，KALESAN B，MATTLE H P，et al.
Percutaneous closure of patent foramen ovale in
cryptogenic embolism[J]. N Engl J Med，2013，368
（12）：1083-1091.
[26] CARROLL J D，SAVER J L，THALER D E，et
al. Closure of patent foramen ovale versus medical
therapy after cryptogenic stroke[J]. N Engl J Med，
2013，368（12）：1092-1100.
[27] SØNDERGAARD L，KASNER S E，RHODES J
F，et al. Patent foramen ovale closure or antiplatelet
therapy for cryptogenic stroke[J]. N Engl J Med，
2017，377（11）：1033-1042.
[28] SAVER J L，CARROLL J D，THALER D E， et al.
Long-term outcomes of patent foramen ovale closure
or medical therapy after stroke[J]. N Engl J Med，
2017，377（11）：1022-1032.
[29] GRAG A，THAWABI M，ROUT A，et al. Recurrent
stroke reduction with patent foramen ovale closure
vursus medical therapy based on patent foramen
ovale characteristics：a meta-analysis of randomized
controlled trails[J]. Cardiology，2019，144（1/2）：
40-49.
[30] MIR H，SIEMIENIUK R A C，GE L，et al. Patent
foramen ovale closure，antiplatelet therapy or
anticoagulation in patients with patent foramen ovale
and cryptogenic stroke：a systematic review and
network meta-analysis incorporating complementary
external evidence[J/OL]. BMJ Open，2018，8（7）：
e023761[2020-07-12]. http：//dx.doi.org/10.1136/
bmjopen-2018-023761.
[31] MESSÉ S R，GRONSETH G，KENT D M，et
al. Practice advisory：recurrent stroke with patent
foramen ovale（update of practice parameter）[J].
Neurology，2016，87（8）：815-821.
[32] KUIJPERS T，SPENCER F A，SIEMIENIUK
R A C，et al. Patent foramen ovale closure，
antiplatelet therapy or anticoagulation therapy
alone for management of cryptogenic stroke?A
clinical practice guideline[J/OL]. BMJ，2018，362：
k2515[2020-07-12]. https：//doi.org/10.1136/bmj.
k2515.
[33] MAS J L，DEREX L，GUÉRIN P，et al. Reprint
of：transcather closure of patent foramen ovale to
prevent stroke recurrence in patients with otherwise
unexplained ischaemic stroke：expert consensus of
the French Neurovascular Society and the French
Society of Cardiology[J]. Rev Neurol（Paris），2020，
176（1/2）：53-61.
[34] MESSÉ S R，GRONSETH G S，KENT D M，et al.
Practice advisory update summary：patent foramen
ovale and secondary stroke prevention：report of the
Guideline Subcommittee of the American Academy
of Neurology[J]. Neurology，2020，94（20）：876-
885.
[35] 张玉顺，蒋世良，朱鲜阳. 卵圆孔未闭相关卒中预防
中国专家指南[J]. 心脏杂志，2021，32（1）：1-10.
[36] SURADI H S，HIJAZI Z M. Patent foramen ovale：

stroke and device closure[J]. Cardiol Clin，2016，34
（2）：231-240.
[37] KHAN R. Examining the evidence for PFO closure
and novel oral anticoagulants for treatment of
cryptogenic stroke[J]. Expert Rev Cardiovasc Ther，
2020，18（3）：139-148.
[38] HORNUNG M，BERTOG S C，FRANKE J，et al.
Long-term results of a randomized trail comparing
three different devices for percutaneous closure of a
patent foramen ovale[J]. Eur Heart J，2013，34（43）：
3362-3369.
[39] MESSÉ S R，SILVERMAN I E，KIZER J R，et
al. Practice parameter：recurrent stroke with patent
foramen ovale and atrial septal aneurysm：report
of the Quality Standards Subcommittee of the
American Academy of Neurology[J]. Neurology，
2004，62（7）：1042-1050.
[40] GEVORGYAN FLEMING R，KUMAR P，WEST
B，et al. Comparison of residual shunt rate and
complications across 6 different closure evices for
patent foramen ovale[J]. Catheter Cardiovasc Interv，
2020，95（3）：365-372.
[41] GIORDANO M，GAIO G，SANTORO G，et
al. Patent foramen ovale with complex anatomy：
comparison of two different devices（Amplatzer
Septal Occluder device and Amplatzer PFO
Occluder device 30/35）[J/OL]. Int J Cardiol，2019，
279：47-50[2020-07-12]. https：//doi.org/10.1016/
j.ijcard.2018.10.053.